[go: up one dir, main page]

PE20010031A1 - Azoles sustituidos como inhibidores de la produccion de tnf - Google Patents

Azoles sustituidos como inhibidores de la produccion de tnf

Info

Publication number
PE20010031A1
PE20010031A1 PE2000000337A PE0003372000A PE20010031A1 PE 20010031 A1 PE20010031 A1 PE 20010031A1 PE 2000000337 A PE2000000337 A PE 2000000337A PE 0003372000 A PE0003372000 A PE 0003372000A PE 20010031 A1 PE20010031 A1 PE 20010031A1
Authority
PE
Peru
Prior art keywords
halogen
alkyl
substituted
phenylethyl
pyrimidinyl
Prior art date
Application number
PE2000000337A
Other languages
English (en)
Inventor
Laszlo Revesz
Achim Schlapbach
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9908531.8A external-priority patent/GB9908531D0/en
Priority claimed from GBGB9908532.6A external-priority patent/GB9908532D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20010031A1 publication Critical patent/PE20010031A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A AZOLES O IMIDAZOLES SUSTITUIDOS DE FORMULA I; DONDE: a ES N, C; b ES CH CUANDO a ES N u O CUANDO a ES C; Z ES N, CH; W ES -NR6-Y-, -O-, -S-; R6 ES H, ALQUILO C1-C4, CICLOALQUILO C3-C8, ARILO C6-C18, HETEROARILO C3-C18, ARALQUILO C7-C19, ENTRE OTROS; R2 ES FENILO OPCIONALMENTE SUSTITUIDO CON HALOGENO, CF3, CIANO, AMIDO, TIOAMIDO, CARBOXILATO, ALCOXILO C1-C4, ALQUILO C1-C4, ENTRE OTROS; R3 ES H, HALOGENO, ALQUILO C1-C10, CICLOALQUILO C3-C10, HETEROCICLOALQUILO C3-C18, ARILO C6-C18, HETEROARILO C3-C18, METILENAMINOGUANIDINILO (-CH=N-NH-C(NH).NH2) OPCIONALMENTE SUSTITUIDO CON ALQUILO C1-C4, HALOGENO, OH, ENTRE OTROS; R5 ES ARILO C6-C18, HETEROARILO C3-C18, CICLOALQUILO C3-C12 OPCIONALMENTE SUSTITUIDO CON ALQUILO C1-C4, HALOGENO, HALOGENO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 4-(4-FLUOROFENIL)-5-(2-[1-(S)-FENILETIL]AMINO-4-PIRIMIDINIL)-2-N-MORFOLINILOXAZOL, 4-(4-FLUOROFENIL)-5-(2-[1-(S)-FENILETIL]AMINO-4-PIRIMIDINIL)-2-N-PIPERIDINILOXAZOL, 3-BROMO-2-(4-FLUOROFENIL)-1-(2-[1-(S)-FENILEETIL]AMINO-4-PIRIMIDINIL)-IMIDAZOL, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCESO PARA LA PREPARACION Y A COMPUESTOS INTERMEDIOS. LOS AZOLES SUSTITUIDOS INHIBEN LA PRODUCCION DE TNFO Y COMO AGENTES ANTIINFLAMATORIOS INMUNOSUPRESORES Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE LA ARTRITIS REUMATOIDE, OSTEOPOROSIS
PE2000000337A 1999-04-14 2000-04-12 Azoles sustituidos como inhibidores de la produccion de tnf PE20010031A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9908531.8A GB9908531D0 (en) 1999-04-14 1999-04-14 Organic compounds
GBGB9908532.6A GB9908532D0 (en) 1999-04-14 1999-04-14 Organic compounds

Publications (1)

Publication Number Publication Date
PE20010031A1 true PE20010031A1 (es) 2001-02-23

Family

ID=26315413

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000337A PE20010031A1 (es) 1999-04-14 2000-04-12 Azoles sustituidos como inhibidores de la produccion de tnf

Country Status (25)

Country Link
US (1) US6579874B2 (es)
EP (1) EP1224180B1 (es)
JP (1) JP2003503311A (es)
KR (1) KR20010108504A (es)
CN (1) CN1378544A (es)
AR (1) AR023465A1 (es)
AT (1) ATE244236T1 (es)
AU (1) AU4295300A (es)
BR (1) BR0010598A (es)
CA (1) CA2370417A1 (es)
CO (1) CO5170501A1 (es)
CZ (1) CZ20013696A3 (es)
DE (1) DE60003709T2 (es)
DK (1) DK1224180T3 (es)
ES (1) ES2202114T3 (es)
HU (1) HUP0302747A2 (es)
IL (1) IL145836A0 (es)
MX (1) MXPA01010434A (es)
NO (1) NO20014987L (es)
PE (1) PE20010031A1 (es)
PL (1) PL364789A1 (es)
PT (1) PT1224180E (es)
SK (1) SK14562001A3 (es)
TR (1) TR200102967T2 (es)
WO (1) WO2000063204A2 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001025220A1 (en) 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
JP2003512467A (ja) * 1999-10-27 2003-04-02 ノバルティス アクチエンゲゼルシャフト チアゾールおよびイミダゾ（４，５−ｂ）ピリジン化合物ならびにそれらの医薬用途
AU2001237041B9 (en) * 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
CZ304059B6 (cs) 2000-12-21 2013-09-11 Glaxo Group Limited Deriváty pyrimidinu a farmaceutický prostredek
EP1354603A1 (en) * 2000-12-26 2003-10-22 Takeda Chemical Industries, Ltd. Concomitant drugs
WO2002062792A1 (en) * 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Jnk inhibitor
AP2002002463A0 (en) 2001-03-09 2002-06-30 Pfizer Prod Inc Novel triazolo-pyrimides anti-inflammatory compounds.
JP2004526727A (ja) * 2001-03-09 2004-09-02 ファイザー・プロダクツ・インク ベンゾイミダゾール抗炎症化合物
ES2247271T3 (es) 2001-04-04 2006-03-01 Pfizer Products Inc. Nuevos benzotriazoles como compuestos antiinflamatorios.
EP1402900A1 (en) * 2001-06-11 2004-03-31 Takeda Chemical Industries, Ltd. Medicinal compositions
TWI231757B (en) * 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
US7109216B2 (en) 2001-09-21 2006-09-19 Solvay Pharmaceuticals B.V. 1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
ES2272809T3 (es) 2001-09-21 2007-05-01 Solvay Pharm Bv Nuevos derivados de 4,5-dihidro-1h-pirazol con actividad antagonista de cb1.
US7473695B2 (en) * 2001-10-22 2009-01-06 Mitsubishi Tanabe Pharma Corporation 4-imidazolin-2-one compounds
JP2005516950A (ja) * 2001-12-19 2005-06-09 メルク　エンド　カムパニー　インコーポレーテッド 代謝型グルタミン酸受容体−５のヘテロアリール置換イミダゾールモジュレータ
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
EP1534282B1 (en) 2002-07-09 2006-12-27 Boehringer Ingelheim Pharma GmbH & Co.KG Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
JP2006502134A (ja) 2002-08-09 2006-01-19 アストラゼネカ アクチボラグ 代謝調節型グルタミン酸受容体において活性を有する化合物
JP4637578B2 (ja) 2002-08-09 2011-02-23 アストラゼネカ アクチボラグ 代謝調節型グルタミン酸受容体−５の調節因子としての１，２，４−オキサジアゾール類
JP2006506340A (ja) * 2002-08-09 2006-02-23 アストラゼネカ アクチボラグ 代謝調節型グルタミン酸受容体５のモジュレーターとしてのオキサジアゾール
US6949652B2 (en) 2002-08-30 2005-09-27 Pfizer, Inc. Crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine
US7012143B2 (en) 2002-08-30 2006-03-14 Dombroski Mark A Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
PA8579601A1 (es) 2002-08-30 2004-05-07 Pfizer Prod Inc Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
US7005523B2 (en) 2002-08-30 2006-02-28 Pfizer Inc. Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
US7037923B2 (en) 2002-08-30 2006-05-02 Pfizer, Inc. Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines
EP1537107A2 (en) * 2002-08-30 2005-06-08 Pfizer Products Inc. Novel processes and intermediates for preparing triazolo-pyridines
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
AU2004209495A1 (en) 2003-02-07 2004-08-19 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivative
MXPA05008568A (es) 2003-02-14 2005-11-04 Pfizer Prod Inc Nuevos compuestos anti-inflamatorios triazolo-piridinas.
TWI326282B (en) * 2004-04-28 2010-06-21 Mitsubishi Tanabe Pharma Corp Heterocyclic compound
JP4803034B2 (ja) 2004-06-30 2011-10-26 Ｍｓｄ株式会社 ビアリール誘導体
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
US9777053B2 (en) * 2006-02-08 2017-10-03 The General Hospital Corporation Methods, arrangements and systems for obtaining information associated with an anatomical sample using optical microscopy
ES2301380B1 (es) 2006-08-09 2009-06-08 Laboratorios Almirall S.A. Nuevos derivados de 1,7-naftiridina.
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
ES2329639B1 (es) 2007-04-26 2010-09-23 Laboratorios Almirall S.A. Nuevos derivados de 4,8-difenilpoliazanaftaleno.
KR20100017508A (ko) 2007-04-30 2010-02-16 아보트 러보러터리즈 디아실글리세롤 ｏ-아실트랜스퍼라제 타입 1 효소의 억제제
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
EP2250160B1 (en) 2008-01-25 2015-11-11 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US9139589B2 (en) 2009-01-30 2015-09-22 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US8759356B2 (en) * 2009-05-19 2014-06-24 Dow Agrosciences, Llc. Compounds and methods for controlling fungi
EP2322176A1 (en) 2009-11-11 2011-05-18 Almirall, S.A. New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
WO2012021615A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US8796268B2 (en) 2010-08-11 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
AU2011316016A1 (en) 2010-10-13 2013-05-30 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
AR086113A1 (es) 2011-04-30 2013-11-20 Abbott Lab Isoxazolinas como agentes terapeuticos
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
WO2018159650A1 (ja) * 2017-02-28 2018-09-07 東レ株式会社 グアニジン誘導体及びその医薬用途
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69433501T2 (de) * 1993-11-08 2004-11-04 Smithkline Beecham Corp. Oxazole zur behandlung von zytokinvermittelten erkrankungen
US5658903A (en) * 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
WO1997005877A1 (en) * 1995-08-10 1997-02-20 Merck & Co., Inc. 2-substituted aryl pyrroles, compositions containing such compounds and methods of use
US6492516B1 (en) * 1999-05-14 2002-12-10 Merck & Co., Inc. Compounds having cytokine inhibitory activity

Also Published As

Publication number Publication date
CA2370417A1 (en) 2000-10-26
PL364789A1 (en) 2004-12-13
PT1224180E (pt) 2003-11-28
US20020049220A1 (en) 2002-04-25
ES2202114T3 (es) 2004-04-01
SK14562001A3 (sk) 2002-03-05
BR0010598A (pt) 2002-02-05
CO5170501A1 (es) 2002-06-27
DE60003709T2 (de) 2004-12-23
DE60003709D1 (de) 2003-08-07
EP1224180B1 (en) 2003-07-02
JP2003503311A (ja) 2003-01-28
CZ20013696A3 (cs) 2002-02-13
KR20010108504A (ko) 2001-12-07
AU4295300A (en) 2000-11-02
AR023465A1 (es) 2002-09-04
ATE244236T1 (de) 2003-07-15
HUP0302747A2 (hu) 2003-12-29
CN1378544A (zh) 2002-11-06
MXPA01010434A (es) 2002-03-27
DK1224180T3 (da) 2003-10-20
EP1224180A2 (en) 2002-07-24
TR200102967T2 (tr) 2002-01-21
WO2000063204A3 (en) 2002-05-23
IL145836A0 (en) 2002-07-25
US6579874B2 (en) 2003-06-17
NO20014987D0 (no) 2001-10-12
NO20014987L (no) 2001-12-14
WO2000063204A2 (en) 2000-10-26

Similar Documents

Publication Publication Date Title
PE20010031A1 (es) Azoles sustituidos como inhibidores de la produccion de tnf
PE20040512A1 (es) Compuesto de pirazol-pirimidina anilina
PE20011039A1 (es) Tiazoles e imidazopiridinas como inhibidores de la produccion de tnf
PE20070189A1 (es) COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA
PE20050087A1 (es) Derivados de 2-oxodihidropiridina n-sustituidos
PE20061353A1 (es) Compuestos de sulfonamida-tiazolopiridina como activadores de glucocinasa
PE20060361A1 (es) Compuestos heterociclicos como inhibidores de la cinesina mitotica
PE20050232A1 (es) Metodo y composiciones para tratar la artritis reumatoide
PE20040590A1 (es) Composiciones de pirrolotriazina anilina como inhibidores de cinasa
CY1107008T1 (el) Παραγωγο βενζιμιδαζολης και χρηση ως ανταγωνιστου υποδοχεα aii
EA200901622A1 (ru) Соединения пиперазина с гербицидным действием
PE20060197A1 (es) Heterociclos biciclicos como inhibidores de cinasa
EA200901659A1 (ru) Соединения пиперазина с гербицидным действием
JP2005529954A5 (es)
CY1112991T1 (el) ΠΑΡΑΓΩΓΑ ΙΝΔΟΛΗΣ Ή ΒΕΝΖΙΜΙΔΑΖΟΛΗΣ ΓΙΑ ΤΗ ΡΥΘΜΙΣΗ ΤΗΣ ΙκΒ ΚΙΝΑΣΗΣ ΚΑΙ ΕΝΔΙΑΜΕΣΑ ΠΡΟΪΟΝΤΑ ΓΙΑ ΤΗΝ ΠΑΡΑΣΚΕΥΗ ΤΟΥΣ
PE20030547A1 (es) Derivados de imidazol para el tratamiento de la obesidad
PE20020753A1 (es) Heteroaromaticos fusionados como activadores de la glucoquinasa
MY134701A (en) Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
ATE443701T1 (de) Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion
UA81561C2 (en) Use of n-arylhydrazine derivative and method for controlling non-crop pests
PE20011008A1 (es) Derivados de pirimidina como inhibidores de ciclooxigenasa 2
PE20040768A1 (es) Derivados de arilen-(2-amino-fenil)-carboxamida como inhibidores de la histona desacetilasa (hdac)
HUP0002808A2 (hu) Eljárás 2-[(3-pirazolil-oxi)-metil]-nitro-benzolok előállítására
PE20070829A1 (es) Inhibidores cetp heterociclicos
MY143245A (en) 4- 2-(cycloalkylamino)pyrimidin-4-yl-(phenyl)-imidazolin-2-one derivatives as p38 map-kinase inhibitors for the treatment of inflammatory diseases

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed